In 1990, a clinical trial for SCID due to adenosine deaminase (ADA) deficiency began, involving ex vivo delivery of the ADA gene to patient-derived T cells using a γ-retroviral vector [34]. This evidence concerns the gene ADA and hyperinsulinemic hypoglycemia, familial, 4.